Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

Université Laval

$814,725.00

Host iNOS dictates gut dysbiosis, bacterial translocation and tissue insulin resistance in murine and human obesity

EF 2021-22

Résumé
Changes in the type of gut microbes (known of the microbiota) can promote obesity and diabetes. We showed that type 2 diabetes alters bacteria in adipose tissues and the liver in obese persons and we now propose that alterations in the immune system and how bacteria adapt may facilitate their presence in metabolic tissues and how they can block insulin action in obesity. A classical mechanism of host defense against bacteria is the production of nitric oxide (NO) by enzyme called iNOS. While iNOS can stop bacterial invaders, it can also causes insulin resistance when unchecked. iNOS expression is also increased in human adipose tissues from persons with obesity and correlates with poor lipid control and inflammation. iNOS expression is also increased in the gut of obesity where it can changes the composition of the gut microbiota. We propose that chronic activation of iNOS in the intestine favors pathogenic bacteria to subvert the gut barrier during obesity. This would allow some of these microbes to breach the intestinal barrier and reach extra-intestinal tissues to impair insulin action. The following hypotheses will be tested : 1) iNOS dictates bacterial tissue invation and insulin resistance in obesity; 2) iNOS is a key determinant of bacterial invasion to human tissues; 3) iNOS invasion in metabolic tissue determines obesity-linked insulin resistance; 4) Restoring intestinal iNOS and microbiota balance will prevent bacterial invasion and prevent diabetes.
Programme
Project Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
453491
Name
Marette André
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Diabetes, Obesity, Lipid & Lipoprotein Disorders
Projecttitle
Host iNOS dictates gut dysbiosis, bacterial translocation and tissue insulin resistance in murine and human obesity
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$814,725
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Bacteria; Glucose Metabolism; Gut; Inflammation; Insulin Resistance; Lipid Metabolism; Microbiome; Mitochondria; Nitric Oxide; Obesity
Abstract
Changes in the type of gut microbes (known of the microbiota) can promote obesity and diabetes. We showed that type 2 diabetes alters bacteria in adipose tissues and the liver in obese persons and we now propose that alterations in the immune system and how bacteria adapt may facilitate their presence in metabolic tissues and how they can block insulin action in obesity. A classical mechanism of host defense against bacteria is the production of nitric oxide (NO) by enzyme called iNOS. While iNOS can stop bacterial invaders, it can also causes insulin resistance when unchecked. iNOS expression is also increased in human adipose tissues from persons with obesity and correlates with poor lipid control and inflammation. iNOS expression is also increased in the gut of obesity where it can changes the composition of the gut microbiota. We propose that chronic activation of iNOS in the intestine favors pathogenic bacteria to subvert the gut barrier during obesity. This would allow some of these microbes to breach the intestinal barrier and reach extra-intestinal tissues to impair insulin action. The following hypotheses will be tested : 1) iNOS dictates bacterial tissue invation and insulin resistance in obesity; 2) iNOS is a key determinant of bacterial invasion to human tissues; 3) iNOS invasion in metabolic tissue determines obesity-linked insulin resistance; 4) Restoring intestinal iNOS and microbiota balance will prevent bacterial invasion and prevent diabetes.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Marette, André
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $814,725~ $0~